Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
NCT01824225 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2015-10-07
Summary
Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.
Conditions
- Age-related Macular Degeneration
Interventions
- DRUG
Sponsors & Collaborators
-
Nihon University
lead OTHER
Principal Investigators
-
Mitsuko Yuzawa, M.D. · Surugadai Nihon University Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2014-03-31
- Completion
- 2015-03-31
Countries
- Japan
More Related Trials
-
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
NCT02181504 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
NCT01722045 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
NCT02821247 ·Status: COMPLETED
-
Non-exudative Age-related Macular Degeneration
NCT01712841 ·Status: COMPLETED
-
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
NCT03382587 ·Status: COMPLETED
-
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
NCT02181517 ·Status: COMPLETED ·Phase: PHASE2
-
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
NCT01657669 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
NCT02204683 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
NCT02418754 ·Status: TERMINATED ·Phase: PHASE2
-
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
NCT03324542 ·Status: COMPLETED
-
Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02120950 ·Status: COMPLETED ·Phase: PHASE4
-
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
NCT02462889 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
NCT01495221 ·Status: COMPLETED ·Phase: PHASE4
-
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
NCT06970665 ·Status: RECRUITING ·Phase: PHASE4
-
Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes
NCT07074054 ·Status: COMPLETED
-
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02401945 ·Status: COMPLETED ·Phase: PHASE2
-
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
NCT01670162 ·Status: UNKNOWN ·Phase: PHASE4
-
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
NCT02541084 ·Status: COMPLETED
-
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
NCT02045212 ·Status: COMPLETED ·Phase: PHASE2
-
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT03714308 ·Status: COMPLETED
-
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
NCT01255462 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
NCT01896284 ·Status: COMPLETED ·Phase: PHASE4
-
Proton Radiation Therapy for Macular Degeneration
NCT01833325 ·Status: COMPLETED ·Phase: NA
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
NCT02713204 ·Status: COMPLETED ·Phase: PHASE2